Designer drug 2,4,5-trimethoxyamphetamine (TMA-2): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques

Journal of Mass Spectrometry

Volumn 41, Issue 9, 2006, Pages 1140-1148

  Ewald, Andreas H ^a   Fritschi, Giselher ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ABT IV 21   (Germany)

Author keywords

GC MS; Metabolism; TMA 2; Urinalysis

Indexed keywords

ALCOHOLS; DRUG DOSAGE; GAS CHROMATOGRAPHY; HYDROLYSIS; KETONES; METABOLISM; TOXIC MATERIALS;

2,4,5-TRIMETHOXYAMPHETAMINE (TMA-2); HUMAN URINE; OXIDATIVE DEAMINATION; SYSTEMATIC TOXICOLOGICAL ANALYSIS (STA);

DRUG PRODUCTS;

1 (2 ACETOXY 4,5 DIMETHOXYPHENYL)ACETONE; 1 (2,4,5 TRIMETHOXYPHENYL)ACETONE; 1 (4 ACETOXY 2,5 DIMETHOXYPHENYL)ACETONE; 1 (5 ACETOXY 2,4 DIMETHOXYPHENYL)ACETONE; 1 METHYL 2 (2,3,5 TRIMETHOXYPHENYL)ETHYL ACETATE; 2,4,5 TRIMETHOXYAMPHETAMINE; ACETIC ACID ETHYL ESTER; ACETONE; ALCOHOL; AMPHETAMINE DERIVATIVE; DRUG METABOLITE; GLUCURONIDE; HYDROXYL GROUP; KETONE; N ACETYL 2 ACETOXY 4,5 DIMETHOXYAMPHETAMINE; N ACETYL 2,4 DIACETOXY 5 METHOXYAMPHETAMINE; N ACETYL 2,5 DIACETOXY 4 METHOXYAMPHETAMINE; N ACETYL 4 ACETOXY 2,5 DIMETHOXYAMPHETAMINE; N ACETYL 4,5 DIACETOXY 2 METHOXYAMPHETAMINE; N ACETYL 5 ACETOXY 2,4 DIMETHOXYAMPHETAMINE; SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEAMINATION; DEMETHYLATION; DOSE RESPONSE; DRUG ACETYLATION; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; URINALYSIS; URINARY EXCRETION;

AMPHETAMINES; ANIMALS; BIOTRANSFORMATION; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; RATS; RATS, WISTAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE ABUSE DETECTION;

EID: 33749032131     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1059     Document Type: Article

References (23)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs. http://www.emcdda.eu.int/multimedia/publications/ risk_assessments/TMA2.2003-1639. pdf, 2004.
2. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci. Int. 2005; 153: 85.
3. Drug Enforcement Administration-Office of Forensic Sciences. Intelligence alert large fentanyl/MDA/TMA laboratory in Azuza, California-possibly the "OC-80" tablet source. Microgram 2006; 39: 45.
4. Shulgin A. Pihkal, A Chemical Love Story, 1st ed. Transform Press: Berkley, 1991.
5. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 1996; 39: 2953.
6. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: Metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives [review]. Ther. Drug Monit. 2002; 24: 277.
7. Staack RF, Maurer HH. Metabolism of Designer Drugs of Abuse [review]. Curr. Drug Metab. 2005; 6: 259.
8. Ewald AH, Peters FT, Weise M, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA). in human urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 824: 123.
9. Ewald AH, Fritschi G, Bork WR, Maurer HH. Designer drugs 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2006; 41: 487.
10. Mitoma C. Metabolic studies on trimethoxyamphetamines. Proc. Soc. Exp. Biol. Med. 1970; 134: 1162.
11. Sargent T, Shulgin AT, Kusubov N III. Quantitative measurement of demethylation of 14C-methoxyl labeled DMPEA and TMA-2 in rats. Psychopharmacol. Commun. 1976; 2: 199.
12. Foster BC, McLeish J, Wilson DL, Whitehouse LW, Zamecnik J, Lodge BA. Biotransformation of tri-substituted methoxyamphetamines by Cunninghamella echinulata. Xenobiotica 1992; 22: 1383.
13. Maurer HH. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control [review]. Clin. Chem. Lab. Med. 2004; 42: 1310.
14. Theobald DS, Fehn S, Maurer HH. New designer drug 2,5-dimethoxy-4- propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2005; 40: 105.
15. Theobald DS, Staack RF, Puetz M, Maurer HH. New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2005; 40: 1157.
16. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. 4th ed. Agilent Technologies: Palo Alto, 2006; in preparation.
17. McLafferty FW, Turecek F. Interpretation of Mass Spectra. 4th ed. University Science Books: Mill Valley 1993.
18. Smith RM, Busch KL. Understanding Mass Spectra - A Basic Approach. Wiley: New York, 1999.
19. Kovats E. Gaschromatographische charakterisierung organischer verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone. Helv. Chim. Acta 1958; 41: 1915.
20. de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special Issue of the TIAFT Bulletin). 3rd ed. VCH publishers: Weinheim, New York, Basle, 1992.
21. Beyer J, Ehlers D, Maurer HH. Abuse of Nutmeg (Myristica fragrans Houtt.): Studies on the metabolism and the toxicological detection of its ingredients elemicin, Myristicin and safrole in rat and human urine using gas chromatography/mass spectrometry. Ther. Drug Monit. 2006; 28: (in press).
22. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002; 773: 35.
23. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001; 23: 61.